Overview of tumor immunotherapy based on approved drugs

2024/01/21 by Ziqin Chen, Tiantian Hu, Jing Zhou +4 · 18 citations
Immunology and Microbiology · Medicine · #Adverse effect #CAR-T cell therapy research #Cancer #Cancer Immunotherapy and Biomarkers #Cancer immunotherapy #Chimeric antigen receptor #Food and drug administration #Immune system #Immunology #Immunotherapy #Immunotherapy and Immune Responses #Internal medicine #Medicine #Oncolytic virus #Pharmacology

paper · doi:10.1016/j.lfs.2024.122419

published in Life Sciences 340, 122419 (Elsevier BV)

openalex publication_date 2024/01/21 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28

Citations

• Cytokines in clinical cancer immunotherapy
• Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
• Cadonilimab: First Approval
• Cancer statistics, 2023

Cited by

• PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy. [europepmc]
• Lipid Nanovesicles in Cancer Treatment: Improving Targeting and Stability of Antisense Oligonucleotides. [europepmc]
• Economic Evaluation of Penpulimab Plus Paclitaxel and Carboplatin Combination Therapy as First-Line Treatment for Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer in China. [europepmc]
• Strategies and efforts in circumventing the emergence of antiviral resistance against conventional antivirals. [europepmc]
• Structural and Functional Insights into a Novel Aspergillus ochraceus Polysaccharide from the Weddell Sea: Implications for Melanoma Immunotherapy In Vitro. [europepmc]
• The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives. [europepmc]
• A Review of Immunotherapy in Renal Cell Carcinoma: Current Landscape and Future Directions. [europepmc]
• Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for extensive-stage small cell lung cancer in China. [europepmc]
• Advancing breast cancer treatment through dual targeting CAR T cell therapy. [europepmc]
• Patient-derived organoids (PDOs): a novel preclinical platform to overcome challenges in cancer immunotherapy. [europepmc]